DEFA14A: Theriva Biologics Seeks Shareholder OK for Warrant Exercise

Theriva Biologics, Inc. is seeking shareholder approval to issue up to 16.18 million common shares upon the exercise of warrants from a recent private placement.

Summary

• A Special Meeting of Stockholders is scheduled for December 15, 2025, at 9:00 A.M. Eastern Time.
• Shareholders will vote on two proposals, both recommended for approval by the Board of Directors.
• Proposal 1 seeks approval, pursuant to Section 713(a) of the NYSE American Company Guide, for the issuance of up to 16,184,560 shares of common stock upon the exercise of warrants issued to institutional investors.
• These warrants were part of a private placement offering that closed on October 17, 2025.
• Proposal 2 requests approval to adjourn the Special Meeting, if necessary, to allow for further solicitation of proxies in the event of insufficient votes for the Warrant Exercise Proposal.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a procedural step to facilitate a past capital raise mechanism. While potential for dilution exists, it's a known aspect of warrant exercises. The board's recommendation for approval is a positive signal.

Positives

• The company is taking necessary steps to facilitate the exercise of previously issued warrants, which could bring in additional capital upon exercise.
• The Board of Directors recommends voting FOR both proposals, indicating management's support for these actions.

Negatives

• Potential for significant share dilution (up to 16,184,560 shares) upon warrant exercise, which could impact existing shareholder value.
• The inclusion of an adjournment proposal suggests a potential risk of insufficient shareholder support for the primary warrant exercise proposal.

Risks

• Risk of insufficient shareholder votes for the Warrant Exercise Proposal, which could delay or prevent the issuance of shares upon warrant exercise.
• Potential for dilution of existing shareholders' ownership percentage and earnings per share if all 16,184,560 shares are issued upon warrant exercise.

Future Outlook

The company is seeking to enable the exercise of warrants, which, if approved, would allow for future capital inflow from warrant holders. The adjournment proposal indicates a contingency plan for ensuring sufficient votes for the primary proposal.

Management Comments

• The Board of Directors recommends you vote FOR proposals 1 and 2.

Industry Context

This filing represents a standard corporate governance step for companies that have issued warrants, particularly when the number of shares to be issued upon exercise exceeds certain exchange thresholds, such as those outlined in NYSE American's Section 713(a). It ensures compliance and transparency with shareholders regarding potential dilution. Many biotech companies, like Theriva Biologics, frequently use private placements and warrant issuances as a capital-raising mechanism due to high R&D costs.

Comparison to Industry Standards

• The requirement for shareholder approval for issuing shares exceeding 20% of outstanding shares (as implied by NYSE American Company Guide Section 713(a)) is a common corporate governance standard across major stock exchanges, designed to protect existing shareholders from significant dilution without their consent.
• The use of private placements with warrants is a frequent capital-raising strategy in the biotechnology sector, often employed by companies in development stages to fund research and clinical trials.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution of ownership and earnings per share if warrants are exercised. However, approval facilitates a previous capital raise.
• Institutional Investors (Warrant Holders): Approval allows them to exercise their warrants and convert them into common stock.

Next Steps

• Shareholders are to vote on the proposals at the Special Meeting on December 15, 2025.
• If Proposal 1 is approved, warrants will be exercisable, leading to the issuance of common stock.
• If Proposal 1 fails to receive sufficient votes, the meeting may be adjourned to solicit additional proxies.

Key Dates

Keywords

Theriva Biologics, Warrants, Shareholder Meeting, Proxy Statement, Private Placement, Stock Dilution, Corporate Governance, NYSE American